Identification

Name
Infliximab
Accession Number
DB00065  (BTD00004, BIOD00004)
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion.

Protein structure
Db00065
Protein chemical formula
C6428H9912N1694O1987S46
Protein average weight
144190.3 Da
Sequences
Not Available
Synonyms
Not Available
External IDs
ABP 710 / BOW015 / CT-P-13 / CT-P13 / TA-650
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FlixabiInjection, powder, for solution100 mgIntravenousSamsung Bioepis Uk Limited (Sbuk)2016-05-26Not applicableEu
FlixabiInjection, powder, for solution100 mgIntravenousSamsung Bioepis Uk Limited (Sbuk)2016-05-26Not applicableEu
FlixabiInjection, powder, for solution100 mgIntravenousSamsung Bioepis Uk Limited (Sbuk)2016-05-26Not applicableEu
FlixabiInjection, powder, for solution100 mgIntravenousSamsung Bioepis Uk Limited (Sbuk)2016-05-26Not applicableEu
FlixabiInjection, powder, for solution100 mgIntravenousSamsung Bioepis Uk Limited (Sbuk)2016-05-26Not applicableEu
InflectraInjection, powder, for solution100 mgIntravenousHospira, Inc.2013-09-10Not applicableEu
InflectraInjection, powder, for solution100 mgIntravenousHospira, Inc.2013-09-10Not applicableEu
InflectraInjection, powder, for solution100 mgIntravenousHospira, Inc.2013-09-10Not applicableEu
InflectraPowder, for solution100 mgIntravenousCelltrion2014-09-04Not applicableCanada
InflectraInjection, powder, for solution100 mgIntravenousHospira, Inc.2013-09-10Not applicableEu
Categories
UNII
B72HH48FLU
CAS number
170277-31-3

Pharmacology

Indication

To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis.

Structured Indications
Pharmacodynamics

Infliximab is a chimeric human-murine anti-human tumor necrosis factor (TNF) monoclonal antibody. It binds to tumor necrosis factor alpha (TNFa) and inhibits binding of TNFa with its receptors. This reduces production of pro-inflammatory cytokines such as interleukins (IL) 1 and 6. This also limits leukocyte migration and expression of adhesion molecules by endothelial cells and leukocytes. Infliximab also limits the activation of neutrophil and eosinophil functional activity, reduces production of tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab decreases synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal.

Mechanism of action

Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa. TNFa activation normally induces the release of proinflammatory cytokines, the enhancement of leukocyte migration and activation of neutrophils among others. Neutralization of the biological activity of TNFa leads to an overall reduction in inflammation.

TargetActionsOrganism
ATumor necrosis factor
inhibitor
Human
Absorption

Onset of action occurs in about 2 weeks in Crohn's disease.

Volume of distribution

3-6 L

Protein binding
Not Available
Metabolism

Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production. Not metabolized by the CYP enzymes.

Route of elimination
Not Available
Half life

9.5 days (7-12 days) in patients with Crohn's disease, plaque psoriasis and rheumatoid arthritis

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Low affinity immunoglobulin gamma Fc region receptor III-A---(C;C)CC Allele (homozygous)Effect Directly StudiedPatients with this genotype have increased ACR20 response when using infliximab to treat rheumatoid arthritis.Details

Interactions

Drug Interactions
DrugInteractionDrug group
AbataceptThe risk or severity of infection can be increased when Infliximab is combined with Abatacept.Approved
AdalimumabAdalimumab may increase the immunosuppressive activities of Infliximab.Approved
AnakinraThe risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Infliximab.Investigational
BelimumabThe risk or severity of adverse effects can be increased when Infliximab is combined with Belimumab.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Infliximab is combined with Canakinumab.Approved, Investigational
Certolizumab pegolInfliximab may increase the immunosuppressive activities of Certolizumab pegol.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.Approved
EtanerceptEtanercept may increase the immunosuppressive activities of Infliximab.Approved, Investigational
FingolimodInfliximab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Infliximab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Infliximab.Investigational
GolimumabGolimumab may increase the immunosuppressive activities of Infliximab.Approved
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Infliximab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Infliximab.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Infliximab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Infliximab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Infliximab is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Infliximab.Approved
RilonaceptThe risk or severity of adverse effects can be increased when Infliximab is combined with Rilonacept.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Infliximab.Investigational
RituximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Infliximab.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Infliximab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Infliximab.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Infliximab.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Infliximab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Infliximab.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Infliximab.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Infliximab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Infliximab.Investigational
TocilizumabTocilizumab may increase the immunosuppressive activities of Infliximab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Infliximab is combined with Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Infliximab.Approved, Investigational
UstekinumabUstekinumab may increase the immunosuppressive activities of Infliximab.Approved, Investigational
VedolizumabThe risk or severity of infection can be increased when Infliximab is combined with Vedolizumab.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Infliximab.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Infliximab.Approved
Food Interactions
Not Available

References

General References
  1. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993 Nov;30(16):1443-53. [PubMed:8232330]
  2. Dubinsky MC, Fleshner PP: Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes. Curr Treat Options Gastroenterol. 2003 Jun;6(3):183-200. [PubMed:12744819]
  3. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398-405. [PubMed:10228190]
  4. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 Feb 26;350(9):876-85. [PubMed:14985485]
  5. Hanauer SB: Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb;17(1):131-7. [PubMed:12617888]
  6. Link [Link]
  7. Link [Link]
External Links
UniProt
P01857
Genbank
J00228
PubChem Substance
46505602
ChEMBL
CHEMBL1201581
Therapeutic Targets Database
DAP000107
PharmGKB
PA452639
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Infliximab
ATC Codes
L04AB02 — Infliximab
AHFS Codes
  • 92:36.00 — Disease-modifying Antirheumatic Agents
FDA label
Download (1.21 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceInflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
1CompletedPreventionReperfusion Injury1
1CompletedTreatmentAnkylosing Spondylitis (AS)3
1CompletedTreatmentGraft Versus Host Disease (GVHD)1
1CompletedTreatmentMucocutaneous Lymph Node Syndrome1
1CompletedTreatmentRheumatoid Arthritis1
1CompletedTreatmentScleritis1
1RecruitingTreatmentDepression1
1RecruitingTreatmentSterile Corneal Melt1
1, 2Not Yet RecruitingTreatmentAneurysms / Strokes / Tumor Necrosis Factor-alpha / Vasculitis1
1, 2TerminatedTreatmentBerylliosis / Beryllium Disease1
1, 2TerminatedTreatmentChronic Granulomatous Disease (CGD) / Crohn'S-like IBD / Inflammatory Bowel Diseases (IBD)1
1, 2Unknown StatusTreatmentDiabetic Macular Edema (DME)1
1, 2WithdrawnPreventionMucous Membrane Pemphigoid / Stevens Johnson Syndrome / Toxic Epidermal Necrolysis (Lyell) Syndrome1
1, 2WithdrawnTreatmentCorneal Blindness / Stevens Johnson Syndrome1
1, 2WithdrawnTreatmentIntraocular Inflammation / Uveitic Macular Edema1
2Active Not RecruitingTreatmentAcute Graft Versus Host Disease / Graft Versus Host Disease (GVHD) / Steroid Refractory GVHD1
2Active Not RecruitingTreatmentLung Cancers / Melanoma / Renal Cell Adenocarcinoma1
2CompletedPreventionGraft Versus Host Disease (GVHD)1
2CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization1
2CompletedTreatmentCachexia / Chronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentCachexia / Neoplasms, Pancreatic1
2CompletedTreatmentChronic Hepatitis C Infection1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentDermatomyositis / Polymyositis1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentEsophagitis1
2CompletedTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis / Renal Limited Vasculitis1
2CompletedTreatmentHidradenitis Suppurativa (HS)1
2CompletedTreatmentMyelodysplastic Syndromes1
2CompletedTreatmentPemphigus1
2CompletedTreatmentPsoriasis2
2CompletedTreatmentRheumatoid Arthritis3
2Not Yet RecruitingTreatmentIdiopathic Refractory Scleritis1
2RecruitingTreatmentAneurysm, Coronary / Mucocutaneous Lymph Node Syndrome1
2RecruitingTreatmentDepression, Bipolar1
2RecruitingTreatmentReperfusion Injury1
2RecruitingTreatmentTakayasu's Disease1
2RecruitingTreatmentTransplant, Kidney1
2TerminatedSupportive CareCancer, Breast / Tiredness1
2TerminatedTreatmentArthritis, Juvenile Rheumatoid1
2TerminatedTreatmentGiant Cells Arteritis1
2TerminatedTreatmentRheumatoid Arthritis1
2TerminatedTreatmentSpondylarthropathy1
2TerminatedTreatmentTropical Spastic Paraparesis1
2Unknown StatusEducational/Counseling/TrainingReactive Arthritis1
2WithdrawnTreatmentColitis / Cytokines / Drug Evaluation / Hermanski-Pudlak Syndrome / Lymphocytes1
2WithdrawnTreatmentToxic Epidermal Necrolysis1
2, 3CompletedNot AvailableAnkylosing Spondylitis (AS)1
2, 3CompletedTreatmentCrohn's Disease (CD)1
2, 3CompletedTreatmentRefractory Myositis1
2, 3CompletedTreatmentSpondylarthropathy1
2, 3TerminatedTreatmentLupus Erythematosus, Systemic / Nephritis, Lupus1
2, 3Unknown StatusTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)1
2, 3WithdrawnTreatmentArthritis1
3Active Not RecruitingTreatmentAnkylosing Spondylitis (AS)1
3Active Not RecruitingTreatmentRheumatoid Arthritis3
3CompletedBasic ScienceCrohn's Disease (CD)1
3CompletedSupportive CareAnorexic / Cachexia / Lung Cancers / Tiredness1
3CompletedTreatmentAnkylosing Spondylitis (AS)3
3CompletedTreatmentAnkylosing Spondylitis (AS) / Spondyloarthritis, Axial1
3CompletedTreatmentBehcet's Syndrome / Neuro-Behcet's Disease1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentCrohn's Disease (CD)7
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
3CompletedTreatmentKawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin1
3CompletedTreatmentMucocutaneous Lymph Node Syndrome2
3CompletedTreatmentPalmoplantar Psoriasis1
3CompletedTreatmentParapsoriasis / Psoriasis1
3CompletedTreatmentPediatric Crohn's Disease1
3CompletedTreatmentPediatric Ulcerative Colitis1
3CompletedTreatmentPlaque Psoriasis / Psoriatic Arthritis / Psoriatic Erythroderma / Pustular Psoriasis (Excluding a Localized)1
3CompletedTreatmentPsoriasis7
3CompletedTreatmentPsoriatic Arthritis2
3CompletedTreatmentRheumatoid Arthritis12
3CompletedTreatmentRheumatoid Arthritis, Juvenile1
3CompletedTreatmentSarcoidosis1
3CompletedTreatmentUlcerative Colitis (UC)4
3Not Yet RecruitingTreatmentCrohn's Disease (CD)1
3Not Yet RecruitingTreatmentRheumatoid Arthritis1
3RecruitingPreventionCrohn's Disease (CD)1
3RecruitingTreatmentBehcet's Syndrome1
3RecruitingTreatmentGraft Versus Host Disease (GVHD)1
3RecruitingTreatmentMucocutaneous Lymph Node Syndrome1
3RecruitingTreatmentRheumatoid Arthritis2
3RecruitingTreatmentUlcerative Colitis (UC)1
3TerminatedPreventionCrohn's Disease (CD)1
3TerminatedTreatmentCrohn's Disease (CD)1
3TerminatedTreatmentDiabetic Macular Edema (DME) / Retinopathy, Diabetic / Visual Acuity1
3TerminatedTreatmentPsoriasis2
3TerminatedTreatmentRheumatoid Arthritis1
3TerminatedTreatmentUlcerative Colitis (UC)2
3Unknown StatusTreatmentCrohn's Disease (CD)1
3Unknown StatusTreatmentPolymyalgia Rheumatica1
4Active Not RecruitingTreatmentRheumatoid Arthritis1
4CompletedNot AvailableAnkylosing Spondylitis (AS) / Crohn's Disease (CD)1
4CompletedNot AvailableAnkylosing Spondylitis (AS) / Psoriasis / Psoriatic Arthritis / Rheumatoid Arthritis1
4CompletedNot AvailableCrohn's Disease (CD) / Psoriasis / Rheumatoid Arthritis1
4CompletedNot AvailableRheumatoid Arthritis1
4CompletedNot AvailableUlcerative Colitis (UC)2
4CompletedDiagnosticAnkylosing Spondylitis (AS)1
4CompletedPreventionCrohn's Disease (CD)1
4CompletedTreatmentAnkylosing Spondylitis (AS)4
4CompletedTreatmentAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Spondylarthropathy1
4CompletedTreatmentBMI >30 kg/m2 / Insulin Resistance / Metabolic Syndromes1
4CompletedTreatmentChronic Uveitis1
4CompletedTreatmentCrohn's Disease (CD)2
4CompletedTreatmentCrohn's Disease (CD) / Psoriasis Chronic / Psoriatic Arthritis / Rheumatoid Arthritis / Spondyloarthritis / Ulcerative Colitis (UC)1
4CompletedTreatmentCrohn's Disease (CD) / Psoriasis / Psoriatic Arthritis / Rheumatoid Arthritis1
4CompletedTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
4CompletedTreatmentDepression1
4CompletedTreatmentGraft Versus Host Disease (GVHD)1
4CompletedTreatmentHypertensive1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentPsoriasis1
4CompletedTreatmentPsoriatic Arthritis1
4CompletedTreatmentRheumatoid Arthritis7
4CompletedTreatmentSpondylitis1
4CompletedTreatmentUlcerative Colitis (UC)1
4CompletedTreatmentUveitis1
4Enrolling by InvitationBasic ScienceRheumatoid Arthritis1
4Enrolling by InvitationTreatmentCrohn's Disease (CD)1
4Not Yet RecruitingTreatmentDepression1
4Not Yet RecruitingTreatmentRheumatoid Arthritis2
4Not Yet RecruitingTreatmentUlcerative Colitis (UC)1
4RecruitingBasic ScienceRheumatoid Arthritis1
4RecruitingOtherHepatosplenic T-Cell Lymphoma1
4RecruitingTreatmentCrohn's Disease (CD)2
4RecruitingTreatmentInflammatory Bowel Diseases (IBD)1
4RecruitingTreatmentRheumatoid Arthritis4
4RecruitingTreatmentUlcerative Colitis (UC)2
4TerminatedDiagnostic(SpA) / Ankylosing Spondylitis (AS)1
4TerminatedTreatmentCrohn's Disease (CD)2
4Unknown StatusBasic ScienceAbsolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern / Psoriasis, Moderate to Severe1
4Unknown StatusScreeningAnkylosing Spondylitis (AS) / Rheumatoid Arthritis1
4Unknown StatusTreatmentAnkylosing Spondylitis (AS) / Hypertensive / Psoriatic Arthritis / Rheumatoid Arthritis1
4Unknown StatusTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentInfliximab / Rheumatoid Arthritis / Ultrasonography1
4Unknown StatusTreatmentRheumatoid Arthritis2
4WithdrawnTreatmentAnkylosing Spondylitis (AS)1
4WithdrawnTreatmentPediatric Crohn's Disease1
Not AvailableActive Not RecruitingNot AvailableAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableActive Not RecruitingNot AvailableCrohn's Disease (CD)1
Not AvailableActive Not RecruitingNot AvailablePsoriasis / Psoriatic Arthritis1
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS)2
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS) / Crohn's Disease (CD) / Psoriasis / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableCompletedNot AvailableAtherosclerosis / Atopic Dermatitis (AD) / Psoriasis1
Not AvailableCompletedNot AvailableCrohn's Disease (CD)5
Not AvailableCompletedNot AvailableCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
Not AvailableCompletedNot AvailableInflammatory Bowel Diseases (IBD) / Psoriasis1
Not AvailableCompletedNot AvailablePsoriasis4
Not AvailableCompletedNot AvailablePsoriatic Arthritis1
Not AvailableCompletedNot AvailableRheumatoid Arthritis6
Not AvailableCompletedNot AvailableSpondyloarthritis / Ultrasonography1
Not AvailableCompletedNot AvailableUveitis1
Not AvailableCompletedBasic ScienceRheumatoid Arthritis1
Not AvailableCompletedScreeningTransplantation, Kidney1
Not AvailableCompletedTreatmentChurg-Strauss Syndrome (CSS) / Granulomatosis With Polyangiitis / Microscopic Polyangiitis1
Not AvailableCompletedTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Pyoderma Gangrenosum / Ulcerative Colitis (UC)1
Not AvailableCompletedTreatmentRheumatoid Arthritis1
Not AvailableCompletedTreatmentUndifferentiated Arthritis1
Not AvailableEnrolling by InvitationNot AvailableCrohn's Disease (CD)1
Not AvailableNot Yet RecruitingTreatmentPediatric Crohns Disease1
Not AvailableNot Yet RecruitingTreatmentUlcerative Colitis (UC)1
Not AvailableRecruitingNot AvailableAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableRecruitingNot AvailableBowel Diseases, Inflammatory / Ulcerative Colitis (UC)1
Not AvailableRecruitingNot AvailableCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)3
Not AvailableRecruitingNot AvailableCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
Not AvailableRecruitingNot AvailableInflammatory Bowel Diseases (IBD)1
Not AvailableRecruitingNot AvailablePsoriasis1
Not AvailableRecruitingNot AvailableRheumatoid Arthritis3
Not AvailableRecruitingDiagnosticInflammatory Bowel Diseases (IBD)1
Not AvailableTerminatedNot AvailableAnkylosing Spondylitis (AS)1
Not AvailableTerminatedNot AvailableCrohn's Disease (CD)2
Not AvailableTerminatedNot AvailableMelanoma1
Not AvailableTerminatedTreatmentCrohn's Disease (CD)1
Not AvailableUnknown StatusNot AvailableCrohn's Disease (CD)1
Not AvailableUnknown StatusNot AvailableScleritis / Uveitis1
Not AvailableUnknown StatusNot AvailableSerological C Reactive Protein or Erythrocyte Sedimentation Rate1
Not AvailableUnknown StatusTreatmentAnkylosing Spondylitis (AS)1
Not AvailableUnknown StatusTreatmentCrohn's Disease (CD)1
Not AvailableUnknown StatusTreatmentPsoriasis1
Not AvailableWithdrawnNot AvailableRheumatoid Arthritis1

Pharmacoeconomics

Manufacturers
  • J&J and Mitsubisi Tanabe
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntravenous100 mg
Powder, for solutionIntravenous100 mg
Injection, powder, lyophilized, for solutionIntravenous100 mg/1
Prices
Unit descriptionCostUnit
Remicade 100 mg Solution Vial821.02USD vial
Remicade 100 mg vial789.44USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2106299No2001-02-062012-03-18Canada

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
hydrophobicity-0.441Not Available
isoelectric point8.25Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Tumor necrosis factor receptor binding
Specific Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac...
Gene Name
TNF
Uniprot ID
P01375
Uniprot Name
Tumor necrosis factor
Molecular Weight
25644.15 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Mimura T: [Selection of one of the TNF blockers; infliximab and etanercept]. Nihon Rinsho. 2007 Jul;65(7):1282-6. [PubMed:17642244]
  3. Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005 Aug;52(8):2447-51. [PubMed:16052578]
  4. Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C: TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006 Feb 15;176(4):2617-24. [PubMed:16456024]
  5. Magro F, Pereira P, Carneiro F, Veloso FT: Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis? Inflamm Bowel Dis. 2005 Jan;11(1):88-90. [PubMed:15674127]
  6. Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, Sugimoto M: Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol. 2006;16(1):58-62. [PubMed:16622728]
  7. Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4 Suppl 2:S22-8. Epub 2002 Mar 27. [PubMed:12110154]
  8. Sapienza MS, Cohen S, Dimarino AJ: Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci. 2004 Sep;49(9):1454-7. [PubMed:15481318]
  9. Tobin AM, Kirby B: TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47-57. [PubMed:15691217]
  10. Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8. [PubMed:15691299]
  11. Popa C, Netea MG, Barrera P, Radstake TR, van Riel PL, Kullberg BJ, Van der Meer JW: Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine. 2005 Apr 21;30(2):72-7. [PubMed:15804598]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34